Global Immuno-oncology Drugs Market: Industry Analysis and Forecast (2020-2026) By Drug Type, Application, End-Users and Region

Global Immuno-oncology Drugs Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 12.4% during the forecast period.

Global Immuno-oncology Drugs Market Overview:

Immuno-oncology is the artificial stimulation of the immune system to treat cancer, improving the immune system's ability to fight the disease. This needs to be personalized because anticancer immune responses can be inhibited in several ways that vary from patient to patient.

Global Immuno-oncology Drugs Market Dynamics:

Technological developments are expected to boost the Immuno-oncology drugs market. Immuno-oncology is considered to be a promising therapy in treating cancer owing to the recent developments in drug discovery and development. The growing number of Immuno-oncology treatments, which are in different phases of clinical trials, and the increasing approval of Immuno-oncology therapies by the FDA are leading to the acceptance of new and advanced technologies in the field of Immuno-oncology therapy. These factors help in propelling the market growth. The increasing prevalence of cancer patients globally serves to be the primary growth factor for the Immuno-oncology drugs market. The rising adoption of immunotherapies over the traditional chemotherapies, increase in popularity of advanced therapies (biological and targeted drug therapies), and surge in the geriatric population worldwide are the key factors driving the growth of the market. According to the WHO, cancer is the second leading cause of death worldwide and an estimated 9.6 million deaths in 2018. The approval of therapeutic solutions in the Immuno-Oncology segment is poised to rapidly increase due to the growing recognition of durable tumour responses. Hence, the competition between pharmaceutical players is intensifying as they strive to achieve first-mover advantages in specific medical applications. However, the high cost involved in new drug development and the threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.

Global Immuno-oncology Drugs Market Segment Analysis:

The Global Immuno-oncology Drugs Market is segmented on the basis of Drug Type, Application and End-Users. Based on Drug Type, the immune checkpoint inhibitors segment is expected to hold a dominant market share and along with this, the CAR T cell therapy segment is expected to witness lucrative growth during the forecast period. The immune checkpoint inhibitors have had remarkable success across multiple malignancies, and are the most well-established therapeutic class of Immuno-oncology agents to date. The immune checkpoint inhibitor, ipilimumab, which is considered a game-changer in cancer treatment received its FDA approval in 2011. Currently, 11 immune checkpoint inhibitors (Table 1) and 2 chimeric antigen receptor T cell (CAR-T) products have been approved in treating 16 types of malignant diseases and 1 tissue-agnostic indication. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system. The CAR T Cell Therapy segment is expected to witness lucrative growth during the forecast period. The rising prevalence of cancer and demand for effective treatment is considered to be the major drivers for the segment growth. In May 2020, researchers from University Hospital Heidelberg, Germany, reported that sufficient yield of lymphocytes for CAR-T cell production is feasible also for patients with low peripheral blood counts. Global Immuno-oncology Drugs Market To know about the Research Methodology :- Request Free Sample Report

Global Immuno-oncology Drugs Market Regional Insights:

Global Immuno-oncology Drugs Market Regional Insights North America is expected to hold a larger market share, followed by Europe during forecast years. The Region is experiencing exponential growth over the last 5 years. It accounted for a market share of 67.1% in 2016 and is experiencing a continuous increase since then. The commercial success is attributed to multiple factors, including speed-to-market, clinical & commercial positioning, marketing approach, and patient group targeting. In recent times, pharma companies are turning to Immuno-Oncology to address some of the most pressing challenges in curing cancer. Various national and international conferences are being arranged such as the Clinical Immuno-Oncology Symposium in Orlando, Florida, organized by ASCO and SITC (Society for Immunotherapy and Cancer), where Scientists, pharma companies, and global healthcare organizations are exchanging research results. Asia Pacific is expected as the fastest-growing region during the forecast period at a CAGR of xx%. The Asia Pacific will command the global market owing to the drivers like improved medical infrastructure, increased patient awareness and rise in disposable income. Cancers with high somatic mutations such as melanoma, lung, bladder, stomach or oesophageal cancer are known to be more responsive to immunotherapies. These cancers are highly prevalent in the Asia-Pacific region. Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies. Many sites across Asia-Pacific have developed a strong track record in managing clinical trials with immunotherapies. Countries such as China, Australia and South Korea are the main locations for these trials with 205, 189 and 76 sites respectively that have been involved in trials for FDA approved Immunotherapies. The market is anticipated to experience fast development in demand for Immuno-oncology drugs in emerging countries such as China, India and South Korea over the forecast period. The report also helps in understanding the Global Immuno-oncology Drugs Market dynamics, structure by analyzing the market segments and project the Global Immuno-oncology Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Immuno-oncology Drugs Market make the report investor’s guide.

Global Immuno-oncology Drugs Market Key developments:

• In June 2020, Targovax, a Norway based biotechnology company, collaborated with the Explorations in Global Health (ExGloH) division of Leidos for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses as a vector to encode MicrotideT checkpoint inhibitor peptides.

Competitive Landscape:

• Bristol-Myers Squibb’s immuno-oncology portfolio is the prime driver of the company’s growth since 2016. Its immuno-oncology drug Opdivo has been approved by FDA for more than ten cancer indications. Regulatory authorities confidently state about Opdivo’s clinical profile to rapidly uptake the global market in a short time span. In 2016, BMS achieved multiple milestones in Opdivo research programs. Altogether, 15 registrational trials were concluded with positive results. Although BMS’s optimistic predictions are reasonably established, the drug is expected to see increased competition from Merck’s Keytruda. • Merck & Co. recorded sales worth USD 1.4 billion in 2016 for their immuno-oncology drug Keytruda. That’s a 148% year-on-year growth as compared to USD566 million in 2015. To highlight its growing success, Keytruda accounted for USD 483 million global sales in the 4th quarter of 2016. The US market accounted for about 65% of the total Keytruda’s sales. Further strengthening their position, Merck & Co. has acquired IOmet, the UK-based drug discovery company focused on cancer metabolism and innovative medicinal drugs for treating cancer. Merck & Co. acquired its comprehensive pre-clinical pipelines

Global Immuno-oncology Drugs Market Scope: Inquire before buying

Global Immuno-oncology Drugs Market

Global Immuno-oncology Drugs Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Immuno-oncology Drugs Market Key players:

• Amgen, Inc. • Astrazeneca Plc • Bristol-Myers Squibb • Celgene Corporation • Eli lilly and Company • Sanofi • F. Hoffmann-La Roche • Novartis AG • Abbvie, Inc. • Pfizer Inc. • Johnson & Johnson • Agenus Inc. • Enzo Biochem, Inc. • Lonza Group • Bio-Rad Laboratories, Inc. • Avantor, Inc. • Spring Bank Pharmaceuticals, Inc. • Ferring Pharmaceuticals
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Immuno-oncology Drugs Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Immuno-oncology Drugs Market 3.4. Geographical Snapshot of the Immuno-oncology Drugs Market, By Manufacturer share 4. Global Immuno-oncology Drugs Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Immuno-oncology Drugs Market 5. Supply Side and Demand Side Indicators 6. Global Immuno-oncology Drugs Market Analysis and Forecast, 2019-2026 6.1. Global Immuno-oncology Drugs Market Size & Y-o-Y Growth Analysis. 7. Global Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 7.1.1. Immune Checkpoint Inhibitors 7.1.2. Monoclonal Antibodies 7.1.3. Cytokine Based Immunotherapy 7.1.4. Cancer Vaccines 7.1.5. CAR-T Cell Therapy 7.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 7.2.1. Melanoma 7.2.2. Lung Cancer 7.2.3. Blood Cancer 7.2.4. Renal Cell Carcinoma 7.2.5. Prostate Cancer 7.2.6. Others 7.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 7.3.1. Hospitals 7.3.2. Clinics 7.3.3. Ambulatory Surgical Centers 8. Global Immuno-oncology Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 9.1.1. Immune Checkpoint Inhibitors 9.1.2. Monoclonal Antibodies 9.1.3. Cytokine Based Immunotherapy 9.1.4. Cancer Vaccines 9.1.5. CAR-T Cell Therapy 9.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 9.2.1. Melanoma 9.2.2. Lung Cancer 9.2.3. Blood Cancer 9.2.4. Renal Cell Carcinoma 9.2.5. Prostate Cancer 9.2.6. Others 9.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 9.3.1. Hospitals 9.3.2. Clinics 9.3.3. Ambulatory Surgical Centers 10. North America Immuno-oncology Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 11.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 12. Canada Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 12.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 13. Mexico Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 13.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 14. Europe Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 14.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 15. Europe Immuno-oncology Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 16.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 17. France Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 17.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 18. Germany Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 18.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 19. Italy Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 19.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 20. Spain Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 20.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 21. Sweden Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 21.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 22. CIS Countries Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 22.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 23. Rest of Europe Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 23.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 24. Asia Pacific Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 24.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 25. Asia Pacific Immuno-oncology Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 26.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 27. India Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 27.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 28. Japan Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 28.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 29. South Korea Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 29.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 30. Australia Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 30.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 31. ASEAN Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 31.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 32. Rest of Asia Pacific Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 32.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 33. Middle East Africa Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 33.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 34. Middle East Africa Immuno-oncology Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 35.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 36. GCC Countries Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 36.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 37. Egypt Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 37.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 38. Nigeria Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 38.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 39. Rest of ME&A Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 39.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 40. South America Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 40.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 41. South America Immuno-oncology Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 42.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 43. Argentina Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 43.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 44. Rest of South America Immuno-oncology Drugs Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Drug Type, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Application, 2019-2026 44.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Immuno-oncology Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Amgen, Inc. 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Astrazeneca Plc 45.3.3. Bristol-Myers Squibb 45.3.4. Celgene Corporation 45.3.5. Eli lilly and Company 45.3.6. Sanofi 45.3.7. F. Hoffmann-La Roche 45.3.8. Novartis AG 45.3.9. Abbvie, Inc. 45.3.10. Pfizer Inc. 45.3.11. Johnson & Johnson 45.3.12. Agenus Inc. 45.3.13. Enzo Biochem, Inc. 45.3.14. Lonza Group 45.3.15. Bio-Rad Laboratories, Inc. 45.3.16. Avantor, Inc. 45.3.17. Spring Bank Pharmaceuticals, Inc. 45.3.18. Ferring Pharmaceuticals 46. Primary Key Insights

About This Report

Report ID 98268
Category Healthcare
Published Date May 2021
Updated Date
Contact Us